Atrial fibrillation combined with cerebral hemorrhage
Conditions
Interventions
Catheter ablation group:Pulsed field ablation (PFA) treatment
Conventional treatment group:Conventional treatment (anticoagulation, blood pressure control, etc., at physician's discretion)
Sponsors
Beijing Anzhen Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age >= 18 years; 2.Between 14 Days and 12 Months After Spontaneous Intracerebral Hemorrhage (sICH); 3.Able to Access Intracerebral Hemorrhage Imaging Data; 4.ECG indicating the presence of atrial fibrillation (AF); 5.CHA2DS2-VA Score >= 2 Points; 6.Willing to undergo randomization and able to complete follow-up as required;
Exclusion criteria
Exclusion criteria: 1. Atrial fibrillation (AF) secondary to clearly reversible causes (e.g., hyperthyroidism, hypokalemia, etc.); 2. Inability to perform activities of daily living (modified Rankin Scale [mRS] score > 4); 3. Complicated with uncontrolled hypertension (systolic blood pressure > 160 mmHg); 4. Presence of conditions associated with a high risk of bleeding, including but not limited to uncontrolled active bleeding, platelet count <100 × 10^9/L, or known or suspected inherited or acquired bleeding or coagulation disorders; 5. Presence of active infection requiring antibiotic treatment; 6. End-stage renal failure or receiving dialysis treatment; 7. Presence of liver failure; 8. Untreated coronary artery disease with indication for revascularization; 9. Presence of intracardiac masses, thrombi, etc., as evaluated by transthoracic echocardiography (TTE) or transesophageal echocardiography (TEE); 10. Expected life expectancy < 1 year (e.g., advanced malignant tumors, etc.); 11. Pregnant, lactating, or women planning to become pregnant; 12. Presence of psychological or psychiatric disorders that prevent understanding or cooperation with the study; 13. Other conditions deemed unsuitable for participation in the study by the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| All-cause mortality, all-cause stroke (including ischemic and hemorrhagic stroke), and systemic embolism; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cardiovascular mortality;Ischemic stroke;Intracerebral hemorrhage;ISTH major bleeding;Quality of life assessment (AFEQT, EQ-5D-5L);Cognitive function assessment (Montreal Cognitive Assessment MoCA, Mini-Mental State Examination MMSE);Modified Rankin Scale (mRS) score; | — |
Countries
China
Contacts
Public ContactMa Changsheng
Beijing Anzhen Hospital, Capital Medical University
Outcome results
None listed